NYSE: BAXBaxter International Inc Stock
$40.23-0.70 (-1.71%)
Updated Apr 25, 2024
BAX Price
$40.23
Fair Value Price
N/A
Market Cap
$20.43B
52 Week Low
$31.01
52 Week High
$50.21
P/E
7.66x
P/B
2.43x
P/S
1.32x
PEG
N/A
Dividend Yield
2.88%
Revenue
$14.81B
Earnings
$2.66B
Gross Margin
33.6%
Operating Margin
20.68%
Profit Margin
17.9%
Debt to Equity
2.36
Operating Cash Flow
$2B
Beta
0.67
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BAX Overview
Baxter International Inc. manufacturfes products to treat kidney disease and other chronic and acute medical conditions. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders, as well as plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions. Baxter's Medical Products segment produces intravenous and other products to deliver fluids and drugs to patients, inhalational anaesthetics, and contract manufacturing services. The company was founded in 1931 and is headquartered in Deerfield, IL.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BAX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BAX is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BAX is good value based on its earnings relative to its share price (7.66x), compared to the US market average (40.97x)
P/E vs Market Valuation
BAX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more BAX due diligence checks available for Premium users.
Be the first to know about important BAX news, forecast changes, insider trades & much more!
BAX News
Valuation
BAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
7.66x
Industry
47.92x
Market
40.97x
BAX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BAX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.43x
Industry
3.49x
BAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BAX's financial health
Profit margin
Revenue
$3.9B
Net Income
$245.0M
Profit Margin
6.3%
BAX's Earnings (EBIT) of $3.06B... subscribe to Premium to read more.
Interest Coverage Financials
BAX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$28.3B
Liabilities
$19.8B
Debt to equity
2.36
BAX's short-term assets ($9.60B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BAX's long-term liabilities ($13.31B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BAX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$531.0M
Investing
-$230.0M
Financing
-$2.9B
BAX's operating cash flow ($1.73B)... subscribe to Premium to read more.
Debt Coverage Financials
BAX vs Medical Stocks
Baxter International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.